Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by Staghorn69on Nov 19, 2017 8:52pm
325 Views
Post# 26993546

RE:Wound Care Market keeps growing - USD$ 22.01 Billion by 2022

RE:Wound Care Market keeps growing - USD$ 22.01 Billion by 2022Good article find...  Makes me shake my head when I read this though - we're doing a trial in Sweden because that's where Dr. Sven Whoever is on a handful of patients that will have to be RE-DONE as a phase 2/3 back in North America...  As time ticks away and other Pharmas are developing drugs for this.  I just wish this was moving a LOT faster...  Given the pot of cash at the end, you'd think there'd be a rush to get a BIG US trial done FAST....
Bullboard Posts